News

Phase II trial approved for TLD-1433

Research Ethics Board approval has been obtained to move TLD-1433 to a Phase II trial for non-muscle invasive bladder cancer, using the therapeutic dose that had shown great success in the now-complete Phase Ib trial. More information can be found in the press release.